29th March 2010 – Inverness Medical has today announced the launch of the new Panbio® Dengue Early Rapid immunochromatographic test for the early detection of dengue infection. Designed for use in conjunction with other dengue serology tests, the Dengue Early Rapid test can help to diagnose active dengue infection from the very first day fever appears. In facilitating early diagnosis, therapy and monitoring can begin much earlier, reducing the risk of severe complications such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS).
Detecting dengue NS1 antigen in serum, the Dengue Early Rapid test is able to provide a specific diagnosis of dengue infection in 15 minutes following an easy three step procedure. This is especially valuable in areas where diagnosis could be confounded by serological cross reactivity. There are four distinct dengue virus serotypes (DEN -1, -2, -3, -4) which are immunologically related and can all cause dengue fever. Although related, the four serotypes do not provide cross-protective immunity against each other, resulting in patients in endemic regions often having more than one infection during their lifetime. The risk of DHF rises substantially with second or subsequent infections, further emphasizing the need for early diagnosis that enables early treatment and care.
Endemic in 124 countries, the dengue virus is carried and transmitted by mosquitoes. Typically, dengue fever is a non-fatal febrile illness characterized by fever, muscle pain, headache, and nausea and vomiting lasting 5-7 days. The more severe manifestations of the disease, dengue hemorrhagic fever and dengue shock syndrome, can however be fatal if not identified and therapy administered in the early stages.
For more information about Panbio® Dengue from Inverness Medical please visit: www.panbiodengue.com
About Inverness Medical
By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life at home. Inverness’ global leading products and services, as well as its new product development efforts, focus on infectious disease, blood borne pathogens, cardiology, oncology, drugs of abuse and women’s health. Inverness is headquartered in Waltham, Massachusetts. For additional information on Inverness Medical Innovations, please visit www.invmed.com.
